Arsenic trioxide inhibits the growth of cancer stem cells derived from small cell lung cancer by downregulating stem cell-maintenance factors and inducing apoptosis via the Hedgehog signaling blockade

BACKGROUND: Small cell lung cancer (SCLC) is the most deadly and aggressive type of primary lung cancer, with the 5-year survival rate lower than 5%. The FDA has approved arsenic trioxide (As(2)O(3)) for acute promyelocytic leukemia (APL) treatment. However, its role in SCLC-derived cancer stem cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Ke-Jie, Yin, Ji-Zhong, Huang, Hai, Li, Bing, Yang, Meng-Hang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481635/
https://www.ncbi.nlm.nih.gov/pubmed/32953511
http://dx.doi.org/10.21037/tlcr-20-467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481635/
https://www.ncbi.nlm.nih.gov/pubmed/32953511
http://dx.doi.org/10.21037/tlcr-20-467

Ejemplares similares